JP2018525037A - 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用 - Google Patents
遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用 Download PDFInfo
- Publication number
- JP2018525037A JP2018525037A JP2018529501A JP2018529501A JP2018525037A JP 2018525037 A JP2018525037 A JP 2018525037A JP 2018529501 A JP2018529501 A JP 2018529501A JP 2018529501 A JP2018529501 A JP 2018529501A JP 2018525037 A JP2018525037 A JP 2018525037A
- Authority
- JP
- Japan
- Prior art keywords
- rna
- nanoparticles
- polynucleotide
- nanoparticle
- isolated polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
【選択図】図1
Description
[0001]本出願は、2015年8月24日に出願された米国仮出願第62/209,278号の優先権を主張し、図面を含めてその全体が参照により本明細書に組み込まれる。
a.一連鎖:<モノヌクレオチド>
b.二連鎖:<ジヌクレオチド>
c.pH連鎖:<pH連鎖>
a.ダイサー1:<5〜12ntループ>
b.rnt1:<13ntステムテトラループ>
c.アプタマー:<アプタマー>
a.MV−RNA Iを標的にする:<一次ガイド><ループ><二次ガイド><アプタマー><キーガイド>
b.MV−RNA IIを標的にする:<一次ガイド><アプタマー><二次ガイド><ループ><キーガイド>
c.MV−RNA IIIを標的にする:<一次ガイド><アプタマー><二次ガイド><プタマー><キーガイド>
d.MV−RNA IIを標的にしない:<一次ガイド><ループ><二次ガイド><ループ><キーガイド>
a.MV−RNAフラグメントの開放:<一次ガイド><ループ><二次ガイド>
b.MV−RNAフラグメントの閉鎖:<キーガイド>
c.MV−RNAフラグメントIIの開放:<一次ガイド>
d.MV−RNAフラグメントIIの閉鎖:<二次ガイド><ループ><キーガイド>
e.RNAフラグメントの開放:<ssRNA 1〜400nt>
f.RNAフラグメントの閉鎖:<上記の「c」と部分的または完全に相補的なssRNA 1〜400nt>
a.5’〜3’の一般的なパターン直鎖状では、<RNAi分子1><連鎖><RNAi分子2><連鎖>,,,..繰り返しである。環状では、<開放配列><RNAi分子1><連鎖><RNAi分子2><連鎖>,,,..繰り返し<閉鎖配列>である。
b.積層MV−RNAナノ粒子の例外(図3B):MV−RNA分子を積層することは、特有のパターンを有して、構造化転写物の完全性を確実にし、高い表面とコアのステム比を作り出す。一般に、追加のMV−RNA配列が、P鎖オーバーハングの前及びS鎖の後の先行MV−RNAのループに挿入され、追加のMV−RNAが、S鎖オーバーハングの後及びK鎖の前に挿入される。<MV−RNA_1一次鎖><2nt OH><MV−RNA_2><2nt OH><MV−RNA_1二次鎖><2nt OH><MV−RNA_3><2nt OH><MV−RNA_1キー鎖><連鎖>,.,.,.,.,.,繰り返し。同じ配列の複数の種類を連鎖するとき、RNAi分子に介在させながら、配列方向の(P、S、K、またはS、K、P、またはK、P、S)を換えることができる。このことは、細胞内分子結合における転写の際に、最近接のワトソンクリック相互作用が交互構造をもたらしうるように助ける。
a.環状化_5:
b.環状化_3
参考文献
1.Adolph & Butler.J Mol Biol 109:345−357(1977)
2.Allison et al.J Virol 62:3581−3588(1988)
3.Annamalai & Rao.Virology 332:650−658(2005)
4.Annamalai & Rao Virology 80:10096−10108(2006)
5.Annamalai et al.J Virol 82:1484−1490(2008)
6.Bamunusinghe & Seo J Virol 85:2953−2963(2011)
7.Bancroft Adv Virus Res 16:99−134(1970)
8.Bancroft & Hiebert Virology 32:354−356(1967)
9.Bancroft et al.Virology 39:924−930(1969)
10.Basnak et al J Mol Biol 395:924−936(2010)
11.Bernstein et al.Nature 409:363−6(2001)
12.Briddon & Markham.Family Geminiviridae,pp.158−165 Murphy FA,et al.(編),Virus taxonomy:archives in virology.Springer−Verlag, New York,NY(1995)
13.Brummelkamp et al.Science 296:550(2002a)
14.Brummelkamp et al.Cancer Cell 2:243(2002b)
15.Cadena−Nava et al.J Phys Chem 115:2386−2391(2011)
16.Caspar & Klug Cold Spring Harbor Symp Quant Biol 27:1−24(1962)
17.Choi & Rao Virology 275:207−217(2000)
18.Choi & Rao Virology 275:249−257(2000)
19.deHaseth et al.Biochemistry 16:4783−4790(1977)
20.Denli et al.Nature 432:231−5(2004)
21.Dreher et al.J Mol Biol 206:425−438(1989)
22.Dzianott & Bujarski Virology 185:553−562(1991)
23.Elrad & Hagan Phys Biol 7:045003(2010)
24.Filippov et al.Gene 245:213−221(2000)
25.Fire et al.Nature 391:806−11(1998)
26.Fox et al.Virology 244:212−218(1998)
27.Frischmuth et al.J Gen Virol 82:673−676(2001)
28.Han et al.Cell 125:887−901(2006)
29.Hiebert et al.Virology 34:492−508(1968)
30.Hu et al.Biophys J 94:1428−1436(2008)
31.Jaronczyk et al.Biochem J 387:561−71(2005)
32.Johnson et al.J Mol Biol 335:455−464(2004)
33.Johnson et al.J Gen Virol 19:263−273(1973)
34.Jung et al.ACS Nano 5:1243−1252(2011)
35.Kim RNA 13:289−294(2007)
36.Kobayashi & Ehara Ann Phytopathol Soc Jpn 61:99−102(1995)
37.Kroll et al.Proc Natl Acad Sci USA 96:13650−13655(1999)
38.Lamontagne J Biol Chem 279:2231−2241(2004)
39. Lavelle et al.J Phys Chem B 113:3813−3820(2009)
40.Logan & Shenk Proc Natl Acad Sci USA 81:3655−3659(1984)
41.Lustig et al.J Virol 62:2329−2336(1988)
42.Macrae et al.Science 311:195−8(2006)
43.Mascotti & Lohman Proc Natl Acad Sci USA 87:3142−3146(1990)
44.Meister & Tuschl Nature 431:343−9(2004)
45.Nugent et al.J Virol 73:427−435(1997)
46.Obenauer−Kutner et al.Hum Gene Ther 13:1687−1696(2002)
47. Perriman & Ares RNA 4:1047−1054(1998)
48.Pfeifer et al.Philos Trans R Soc Lond B Biol Sci 276:99−107(1976)
49.Porterfield et al.J Virol 84:7174−7184(2010)
50.Prinsen et al.J Phys Chem B 114:5522−5533(2010)
51.Qu & Morris J Virol 71:1428−1435(1997)
52.Rao Annu Rev Phytopathol 44:61−87(2006)
53.Sambrook et al.Molecular cloning:a laboratory manual.Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NY(1989)
54.Sidahmed & Bruce Methods Mol Biol 623:3−19(2010)
55.Sikkema et al.Org Biomol Chem 5:54−57(2007)
56.Song et al.Nat Struct Biol 10:1026−32(2003)
57.Sorger et al.J Mol Biol 191:639−658(1986)
58.Speir et al.Structure 3:63−78(1995)
59.Sun et al.Proc Natl Acad Sci USA 104:1354−1359(2007)
60.Tang et al.J Struct Biol 154:59−67(2006)
61.Turner et al.Insect Mol Biol 15:383−391(2006)
62.van der Graaf et al.Biochem 3:9177−9182(1992)
63.Venter et al.J Virol 79:6239−6248(2005)
64.Verduin & Bancroft Virology 37:501−506(1969)
65.Yoffe et al.Proc Natl Acad Sci USA 105:16153−16158(2008)
66.Zandi & van der Schoot Biophys J. 96:9−20(2009)
67.Zhang et al.Virology 279:471−477(2001)
68.Zlotnick et al.Virology 277:450−456(2000)
配列番号89:AKT(プロテインキナーゼBのX61037 H.sapiens mRNA):
参考文献
1.Adolph & Butler.J Mol Biol 109:345−357(1977)
2.Allison et al.J Virol 62:3581−3588(1988)
3.Annamalai & Rao.Virology 332:650−658(2005)
4.Annamalai & Rao Virology 80:10096−10108(2006)
5.Annamalai et al.J Virol 82:1484−1490(2008)
6.Bamunusinghe & Seo J Virol 85:2953−2963(2011)
7.Bancroft Adv Virus Res 16:99−134(1970)
8.Bancroft & Hiebert Virology 32:354−356(1967)
9.Bancroft et al.Virology 39:924−930(1969)
10.Basnak et al J Mol Biol 395:924−936(2010)
11.Bernstein et al.Nature 409:363−6(2001)
12.Briddon & Markham.Family Geminiviridae,pp.158−165 Murphy FA,et al.(編),Virus taxonomy:archives in virology.Springer−Verlag, New York,NY(1995)
13.Brummelkamp et al.Science 296:550(2002a)
14.Brummelkamp et al.Cancer Cell 2:243(2002b)
15.Cadena−Nava et al.J Phys Chem 115:2386−2391(2011)
16.Caspar & Klug Cold Spring Harbor Symp Quant Biol 27:1−24(1962)
17.Choi & Rao Virology 275:207−217(2000)
18.Choi & Rao Virology 275:249−257(2000)
19.deHaseth et al.Biochemistry 16:4783−4790(1977)
20.Denli et al.Nature 432:231−5(2004)
21.Dreher et al.J Mol Biol 206:425−438(1989)
22.Dzianott & Bujarski Virology 185:553−562(1991)
23.Elrad & Hagan Phys Biol 7:045003(2010)
24.Filippov et al.Gene 245:213−221(2000)
25.Fire et al.Nature 391:806−11(1998)
26.Fox et al.Virology 244:212−218(1998)
27.Frischmuth et al.J Gen Virol 82:673−676(2001)
28.Han et al.Cell 125:887−901(2006)
29.Hiebert et al.Virology 34:492−508(1968)
30.Hu et al.Biophys J 94:1428−1436(2008)
31.Jaronczyk et al.Biochem J 387:561−71(2005)
32.Johnson et al.J Mol Biol 335:455−464(2004)
33.Johnson et al.J Gen Virol 19:263−273(1973)
34.Jung et al.ACS Nano 5:1243−1252(2011)
35.Kim RNA 13:289−294(2007)
36.Kobayashi & Ehara Ann Phytopathol Soc Jpn 61:99−102(1995)
37.Kroll et al.Proc Natl Acad Sci USA 96:13650−13655(1999)
38.Lamontagne J Biol Chem 279:2231−2241(2004)
39. Lavelle et al.J Phys Chem B 113:3813−3820(2009)
40.Logan & Shenk Proc Natl Acad Sci USA 81:3655−3659(1984)
41.Lustig et al.J Virol 62:2329−2336(1988)
42.Macrae et al.Science 311:195−8(2006)
43.Mascotti & Lohman Proc Natl Acad Sci USA 87:3142−3146(1990)
44.Meister & Tuschl Nature 431:343−9(2004)
45.Nugent et al.J Virol 73:427−435(1997)
46.Obenauer−Kutner et al.Hum Gene Ther 13:1687−1696(2002)
47. Perriman & Ares RNA 4:1047−1054(1998)
48.Pfeifer et al.Philos Trans R Soc Lond B Biol Sci 276:99−107(1976)
49.Porterfield et al.J Virol 84:7174−7184(2010)
50.Prinsen et al.J Phys Chem B 114:5522−5533(2010)
51.Qu & Morris J Virol 71:1428−1435(1997)
52.Rao Annu Rev Phytopathol 44:61−87(2006)
53.Sambrook et al.Molecular cloning:a laboratory manual.Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NY(1989)
54.Sidahmed & Bruce Methods Mol Biol 623:3−19(2010)
55.Sikkema et al.Org Biomol Chem 5:54−57(2007)
56.Song et al.Nat Struct Biol 10:1026−32(2003)
57.Sorger et al.J Mol Biol 191:639−658(1986)
58.Speir et al.Structure 3:63−78(1995)
59.Sun et al.Proc Natl Acad Sci USA 104:1354−1359(2007)
60.Tang et al.J Struct Biol 154:59−67(2006)
61.Turner et al.Insect Mol Biol 15:383−391(2006)
62.van der Graaf et al.Biochem 3:9177−9182(1992)
63.Venter et al.J Virol 79:6239−6248(2005)
64.Verduin & Bancroft Virology 37:501−506(1969)
65.Yoffe et al.Proc Natl Acad Sci USA 105:16153−16158(2008)
66.Zandi & van der Schoot Biophys J. 96:9−20(2009)
67.Zhang et al.Virology 279:471−477(2001)
68.Zlotnick et al.Virology 277:450−456(2000)
配列番号89:AKT(プロテインキナーゼBのX61037 H.sapiens mRNA):
[1]
直径がおよそ40nmであり、外面が中心の少なくとも2倍のステム比を有する単離ポリヌクレオチドナノ粒子であって、2つ以上の接続されたMV−RNA配列を含み、それぞれのMV−RNA配列が連鎖要素によって離されている、単離ポリヌクレオチドナノ粒子。
[2]
直径がおよそ100nmであり、外面が中心の少なくとも4倍のステム比を有する単離ポリヌクレオチドナノ粒子であって、3つのMV−RNAの積層セットを含み、それぞれの積層MV−RNAセットが連結要素によって離されている、単離ポリヌクレオチドナノ粒子。
[3]
前記ポリヌクレオチドナノ粒子が、1つまたは表面ループにアプタマーまたは細胞取り込み配列を含有する、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[4]
前記ポリヌクレオチドナノ粒子が、図1〜3のいずれか1つに記載されている一般的構造を有する、[1]に記載の単離ポリヌクレオチドナノ粒子。
[5]
前記ポリヌクレオチドナノ粒子が、(i)閉鎖配列として作用する、単一MV−RNAの5’末端及び同じMV−RNAの3’末端、または(ii)閉鎖配列として作用するdsRNAを含有する、[1]に記載の単離ポリヌクレオチドナノ粒子。
[6]
前記連鎖要素が、エンドヌクレアーゼにより切断可能な、(i)ステムループ構造、または(ii)ジヌクレオチド、または(iii)モノヌクレオチドを含む、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[7]
前記ポリヌクレオチドナノ粒子が、天然または合成のRNAまたはDNAを含む、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[8]
前記切断可能な連鎖配列が、3〜12個のヌクレオチドである、[1]〜[12]のいずれか一に記載の単離ポリヌクレオチドナノ粒子。
[9]
前記ポリヌクレオチドナノ粒子が、リボザイム切断により環状化された単一ポリヌクレオチドナノ粒子である、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[10]
前記ポリヌクレオチドナノ粒子が、植物細胞、もしくはヒト細胞、もしくは酵母細胞、もしくは細菌細胞から選択される宿主細胞内において、またはインビトロ転写によって発現する、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[11]
前記ポリヌクレオチドナノ粒子が、宿主細胞内において発現し、前記宿主以外の遺伝子を標的にする、[1]または[2]に記載の単離ポリヌクレオチドナノ粒子。
[12]
[1]〜[9]のいずれか一に記載の単離ポリヌクレオチドナノ粒子を、生理学的に許容される賦形剤と組み合わせて含む、組成物。
Claims (12)
- 直径がおよそ40nmであり、外面が中心の少なくとも2倍のステム比を有する単離ポリヌクレオチドナノ粒子であって、2つ以上の接続されたMV−RNA配列を含み、それぞれのMV−RNA配列が連鎖要素によって離されている、単離ポリヌクレオチドナノ粒子。
- 直径がおよそ100nmであり、外面が中心の少なくとも4倍のステム比を有する単離ポリヌクレオチドナノ粒子であって、3つのMV−RNAの積層セットを含み、それぞれの積層MV−RNAセットが連結要素によって離されている、単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、1つまたは表面ループにアプタマーまたは細胞取り込み配列を含有する、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、図1〜3のいずれか1つに記載されている一般的構造を有する、請求項1に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、(i)閉鎖配列として作用する、単一MV−RNAの5’末端及び同じMV−RNAの3’末端、または(ii)閉鎖配列として作用するdsRNAを含有する、請求項1に記載の単離ポリヌクレオチドナノ粒子。
- 前記連鎖要素が、エンドヌクレアーゼにより切断可能な、(i)ステムループ構造、または(ii)ジヌクレオチド、または(iii)モノヌクレオチドを含む、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、天然または合成のRNAまたはDNAを含む、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 前記切断可能な連鎖配列が、3〜12個のヌクレオチドである、請求項1〜12のいずれか一項に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、リボザイム切断により環状化された単一ポリヌクレオチドナノ粒子である、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、植物細胞、もしくはヒト細胞、もしくは酵母細胞、もしくは細菌細胞から選択される宿主細胞内において、またはインビトロ転写によって発現する、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 前記ポリヌクレオチドナノ粒子が、宿主細胞内において発現し、前記宿主以外の遺伝子を標的にする、請求項1または2に記載の単離ポリヌクレオチドナノ粒子。
- 請求項1〜9のいずれか一項に記載の単離ポリヌクレオチドナノ粒子を、生理学的に許容される賦形剤と組み合わせて含む、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562209278P | 2015-08-24 | 2015-08-24 | |
US62/209,278 | 2015-08-24 | ||
PCT/US2016/048492 WO2017035278A1 (en) | 2015-08-24 | 2016-08-24 | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018525037A true JP2018525037A (ja) | 2018-09-06 |
Family
ID=58101197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018529501A Pending JP2018525037A (ja) | 2015-08-24 | 2016-08-24 | 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10731157B2 (ja) |
EP (1) | EP3340967B1 (ja) |
JP (1) | JP2018525037A (ja) |
CN (1) | CN108366966A (ja) |
AU (1) | AU2016312530A1 (ja) |
BR (1) | BR112018003784A2 (ja) |
CA (1) | CA2995995A1 (ja) |
IL (1) | IL257376B (ja) |
MX (1) | MX2018002090A (ja) |
WO (1) | WO2017035278A1 (ja) |
ZA (1) | ZA201800977B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011207563B2 (en) | 2010-01-19 | 2016-03-10 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
WO2015023797A1 (en) | 2013-08-13 | 2015-02-19 | Northwestern University | Lipophilic nanoparticles for drug delivery |
CN112107693B (zh) | 2013-12-03 | 2023-05-26 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
ES2725948T3 (es) | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
EP3204499A4 (en) | 2014-10-06 | 2018-04-25 | Exicure, Inc. | Anti-tnf compounds |
CN107106493A (zh) | 2014-11-21 | 2017-08-29 | 西北大学 | 球形核酸纳米颗粒缀合物的序列特异性细胞摄取 |
BR112018003784A2 (pt) | 2015-08-24 | 2018-09-25 | Halo-Bio Rnai Therapeutics, Inc. | nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização |
US20190142739A1 (en) * | 2016-04-19 | 2019-05-16 | Exicure, Inc. | Topical administration of therapeutic agents and oligonucleotide formulations |
AU2017261360A1 (en) | 2016-05-06 | 2018-11-29 | Exicure Operating Company | Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
MX2020000387A (es) | 2017-07-13 | 2020-08-17 | Univ Northwestern | Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos. |
US20230151370A1 (en) * | 2017-07-14 | 2023-05-18 | Halo-Bio Rnai Therapeutics, Inc. | Methods and compositions for aptamer-driven surface formulation of self-forming polynucleotide nanoparticles |
MX2021011205A (es) * | 2019-03-18 | 2021-12-10 | Sound Agriculture Company | Control epigenetico programable de expresion genica en plantas. |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
DE3650349T2 (de) | 1985-03-15 | 1995-12-14 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren. |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5569597A (en) | 1985-05-13 | 1996-10-29 | Ciba Geigy Corp. | Methods of inserting viral DNA into plant material |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5268463A (en) | 1986-11-11 | 1993-12-07 | Jefferson Richard A | Plant promoter α-glucuronidase gene construct |
US5608142A (en) | 1986-12-03 | 1997-03-04 | Agracetus, Inc. | Insecticidal cotton plants |
US5023179A (en) | 1988-11-14 | 1991-06-11 | Eric Lam | Promoter enhancer element for gene expression in plant roots |
US5110732A (en) | 1989-03-14 | 1992-05-05 | The Rockefeller University | Selective gene expression in plants |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
EP0452269B1 (en) | 1990-04-12 | 2002-10-09 | Syngenta Participations AG | Tissue-preferential promoters |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5498830A (en) | 1990-06-18 | 1996-03-12 | Monsanto Company | Decreased oil content in plant seeds |
US5459252A (en) | 1991-01-31 | 1995-10-17 | North Carolina State University | Root specific gene promoter |
US5399680A (en) | 1991-05-22 | 1995-03-21 | The Salk Institute For Biological Studies | Rice chitinase promoter |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
HU219057B (hu) | 1991-08-27 | 2001-02-28 | Novartis Ag. | Inszekticid hatású proteinek Homoptera rovarok ellen és alkalmazásuk a növényvédelemben |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
JPH06511152A (ja) | 1991-10-04 | 1994-12-15 | ノースカロライナ ステイト ユニバーシティー | 病原体耐性トランスジェニック植物 |
US5428148A (en) | 1992-04-24 | 1995-06-27 | Beckman Instruments, Inc. | N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis |
US5401836A (en) | 1992-07-16 | 1995-03-28 | Pioneer Hi-Bre International, Inc. | Brassica regulatory sequence for root-specific or root-abundant gene expression |
US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
CA2165162C (en) | 1993-06-14 | 2000-05-23 | Hermann Bujard | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5633363A (en) | 1994-06-03 | 1997-05-27 | Iowa State University, Research Foundation In | Root preferential promoter |
US5608144A (en) | 1994-08-12 | 1997-03-04 | Dna Plant Technology Corp. | Plant group 2 promoters and uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
CA2200952C (en) | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5659026A (en) | 1995-03-24 | 1997-08-19 | Pioneer Hi-Bred International | ALS3 promoter |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5837876A (en) | 1995-07-28 | 1998-11-17 | North Carolina State University | Root cortex specific gene promoter |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20040171031A1 (en) | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US6072050A (en) | 1996-06-11 | 2000-06-06 | Pioneer Hi-Bred International, Inc. | Synthetic promoters |
US5874554A (en) | 1996-12-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices |
EP1027033B1 (en) | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
CA2315549A1 (en) | 1998-02-26 | 1999-09-02 | Pioneer Hi-Bred International, Inc. | Family of maize pr-1 genes and promoters |
AU762993C (en) | 1998-02-26 | 2004-06-10 | Pioneer Hi-Bred International, Inc. | Constitutive maize promoters |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
DE69928264T2 (de) | 1998-08-20 | 2006-07-13 | Pioneer Hi-Bred International, Inc. | Samen-bevorzugende promotoren |
WO2000012733A1 (en) | 1998-08-28 | 2000-03-09 | Pioneer Hi-Bred International, Inc. | Seed-preferred promoters from end genes |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
AU783647B2 (en) | 1999-04-20 | 2005-11-17 | University Of British Columbia, The | Cationic peg-lipids and methods of use |
US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
WO2000068405A2 (en) | 1999-05-07 | 2000-11-16 | E.I. Du Pont De Nemours And Company | Plant defensins |
US6770750B2 (en) | 1999-11-18 | 2004-08-03 | Korea Kumho Petrochemical Co., Ltd. | Small and cysteine rich antifungal defensin and thionin-like protein genes highly expressed in the incompatible interaction |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
US20070270579A1 (en) | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20070173473A1 (en) | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
US20050196781A1 (en) | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
MXPA03011890A (es) | 2001-06-22 | 2004-06-03 | Du Pont | Polinucleotidos de defensina y metodos de uso. |
ES2275015T3 (es) | 2001-07-13 | 2007-06-01 | Pioneer Hi-Bred International, Inc. | Promotores especificos de tejido vascular. |
CA2936534C (en) | 2001-07-23 | 2021-01-26 | The Board Of Trustees Of Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20030106097A1 (en) | 2001-07-30 | 2003-06-05 | Haigler Candace H. | Chitinase encoding DNA molecule from cotton expressed preferentially in fibers during secondary cell wall deposition and the corresponding promoter |
CA2459347C (en) | 2001-09-04 | 2012-10-09 | Exiqon A/S | Locked nucleic acid (lna) compositions and uses thereof |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
WO2004030634A2 (en) | 2002-10-02 | 2004-04-15 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
EP1572964A4 (en) | 2002-10-18 | 2007-08-08 | Nucleonics Inc | STRUCTURES AND CONSTRUCTIONS OF DOUBLE STRANDED RNA AND METHODS FOR THEIR GENERATION AND USE |
JP2004261002A (ja) | 2003-01-08 | 2004-09-24 | Tsutomu Suzuki | siRNAの製造方法 |
WO2004064737A2 (en) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Therapeutics compositions |
EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
CA2488224A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
US20070179100A1 (en) | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
WO2004091515A2 (en) | 2003-04-09 | 2004-10-28 | Alnylam Pharmaceuticals, Inc. | iRNA CONJUGATES |
WO2004091572A2 (en) | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
CA2522349A1 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals, Inc. | Protected monomers |
EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP1635763B1 (en) | 2003-06-09 | 2012-08-08 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
ES2905724T3 (es) | 2003-06-13 | 2022-04-11 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
US7803397B2 (en) | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
WO2005027979A2 (en) | 2003-09-17 | 2005-03-31 | Let There Be Hope Medical Research Institute | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
EP1689414A4 (en) * | 2003-12-04 | 2009-04-08 | Univ South Florida Res Foundat | POLYNUCLEOTIDES FOR REDUCING GENE EXPRESSION OF THE RESPIRATORY SYNCYTIAL VIRUS |
AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
CA2561741C (en) | 2004-04-05 | 2016-09-27 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for oligonucleotide synthesis and purification |
WO2006078278A2 (en) | 2004-04-27 | 2006-07-27 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
JP4584987B2 (ja) | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | C5修飾ピリミジンを含むオリゴヌクレオチド |
US7928217B2 (en) | 2004-05-27 | 2011-04-19 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
WO2005115471A2 (en) | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
AU2005327517B2 (en) | 2004-06-30 | 2011-05-26 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
AU2005328382C1 (en) | 2004-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
AU2005330637B2 (en) | 2004-08-04 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 化学修飾オリゴヌクレオチド |
AU2005289588B2 (en) | 2004-09-24 | 2011-12-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
EP1814597A4 (en) | 2004-11-24 | 2009-04-22 | Alnylam Pharmaceuticals Inc | RNAI MODULATION OF BCR-ABL FUSION GENE AND APPLICATIONS THEREOF |
EP1819365B1 (en) | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
JP2008523157A (ja) | 2004-12-14 | 2008-07-03 | アルナイラム ファーマシューティカルズ インコーポレイテッド | MLL−AF4のRNAi調節およびその使用方法 |
EP1824967B1 (en) | 2004-12-21 | 2014-11-05 | Monsanto Technology, LLC | Recombinant dna constructs and methods for controlling gene expression |
EP1831401B1 (en) | 2004-12-29 | 2010-02-10 | Applied Biosystems, LLC | Methods, compositions, and kits for forming self-complementary polynucleotides |
US7507809B2 (en) | 2005-01-07 | 2009-03-24 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
CA2594919A1 (en) | 2005-01-24 | 2006-08-03 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of the nogo-l or nogo-r gene and uses thereof |
US7718625B2 (en) | 2005-01-27 | 2010-05-18 | University Of South Florida | Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof |
NZ560936A (en) | 2005-02-03 | 2010-04-30 | Benitec Inc | RNAI expression constructs |
CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
EP1896084A4 (en) | 2005-06-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | RNAI MODULATION OF HIF-1 AND THERAPEUTIC APPLICATIONS THEREOF |
JP2009502138A (ja) | 2005-07-21 | 2009-01-29 | アルナイラム ファーマシューティカルズ インコーポレイテッド | RhoA遺伝子のRNAi調節及びその使用法 |
CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
WO2007021896A2 (en) | 2005-08-10 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20070148246A1 (en) | 2005-08-11 | 2007-06-28 | Dan Luo | Nucleic Acid-Based Matrixes |
US20100136614A1 (en) * | 2005-10-18 | 2010-06-03 | Dan Luo | Dendrimer-like modular delivery vector |
EP1937066A4 (en) | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
JP5111385B2 (ja) | 2005-10-28 | 2013-01-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ハンチンチン遺伝子の発現を抑制するための組成物および方法 |
KR20080086440A (ko) | 2005-11-01 | 2008-09-25 | 알닐람 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 RNAi 억제 |
EP1942948A4 (en) | 2005-11-04 | 2010-03-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE |
EP1945270B1 (en) | 2005-11-09 | 2011-05-25 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
CA2527144C (en) | 2005-11-15 | 2014-04-29 | Queen's University At Kingston | Reversibly switchable surfactants and methods of use thereof |
EP1951870B1 (de) | 2005-11-25 | 2013-04-24 | Mologen AG | Dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz |
US8362229B2 (en) | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
WO2007109097A2 (en) | 2006-03-16 | 2007-09-27 | Alnylam Pharmaceuticals, Inc. | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
KR101547579B1 (ko) | 2006-03-31 | 2015-08-27 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산 |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
SI2024499T1 (en) | 2006-05-10 | 2018-04-30 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
NZ587616A (en) | 2006-05-11 | 2012-03-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the pcsk9 gene |
EP2016173A4 (en) | 2006-05-15 | 2010-06-09 | Immunomedics Inc | METHOD AND COMPOSITIONS FOR TREATING HUMAN IMMUNODEFECT VIRUS INFECTIONS WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS |
WO2007137237A2 (en) | 2006-05-19 | 2007-11-29 | The Scripps Research Institute | Treatment of protein misfolding |
ATE528008T1 (de) | 2006-05-19 | 2011-10-15 | Alnylam Pharmaceuticals Inc | Rnai-modulation von aha und ihre therapeutische verwendung |
EP2192200B1 (en) | 2006-05-22 | 2012-10-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US8124752B2 (en) | 2006-07-10 | 2012-02-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the MYC gene |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CA2663803A1 (en) | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of scap and therapeutic uses thereof |
EP2066687A4 (en) | 2006-09-21 | 2010-12-08 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE |
US7906484B2 (en) | 2006-09-21 | 2011-03-15 | Alnylam Pharmaceuticals, Inc. | Complex for transferring an anionic substance into a cell |
MX2009003548A (es) | 2006-10-03 | 2009-04-15 | Alnylam Pharmaceuticals Inc | Formulaciones que contienen lipidos. |
JP5876637B2 (ja) | 2006-10-18 | 2016-03-02 | マリーナ バイオテック,インコーポレイテッド | ニックまたはギャップの入った核酸分子およびそれらの使用 |
US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
EP2147102B1 (en) | 2007-03-29 | 2014-01-15 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
AU2008242583B2 (en) | 2007-04-23 | 2013-10-10 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
WO2009018332A1 (en) | 2007-08-01 | 2009-02-05 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
KR101617472B1 (ko) | 2007-11-15 | 2016-05-02 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 모르폴리노 올리고머의 합성 방법 |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
WO2009076321A2 (en) | 2007-12-07 | 2009-06-18 | Halo-Bio Rnai Therapeutics Inc. | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
CA3044134A1 (en) | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
US8883211B2 (en) | 2008-07-10 | 2014-11-11 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010078516A2 (en) | 2009-01-01 | 2010-07-08 | Cornell University | Multifunctional nucleic acid nano-structures |
KR101169373B1 (ko) | 2009-02-04 | 2012-07-30 | 성균관대학교산학협력단 | 세포 내 전달능이 증가된 작은 간섭 rna 복합체 |
WO2010135716A1 (en) | 2009-05-22 | 2010-11-25 | The Research Foundation Of State University Of New York | Trans-acting rna switches |
CA2764158A1 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
CN103403189B (zh) * | 2011-06-08 | 2015-11-25 | 辛辛那提大学 | 用于稳定的多价RNA纳米颗粒中的pRNA多价连接域 |
WO2014059022A1 (en) * | 2012-10-09 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use |
CA2924509A1 (en) | 2013-09-17 | 2015-03-26 | Bruce Allen Shapiro | Multifunctional rna nanoparticles and methods of use |
BR112018003784A2 (pt) | 2015-08-24 | 2018-09-25 | Halo-Bio Rnai Therapeutics, Inc. | nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização |
-
2016
- 2016-08-24 BR BR112018003784-2A patent/BR112018003784A2/pt active Search and Examination
- 2016-08-24 CN CN201680054186.6A patent/CN108366966A/zh active Pending
- 2016-08-24 AU AU2016312530A patent/AU2016312530A1/en not_active Abandoned
- 2016-08-24 MX MX2018002090A patent/MX2018002090A/es unknown
- 2016-08-24 CA CA2995995A patent/CA2995995A1/en active Pending
- 2016-08-24 JP JP2018529501A patent/JP2018525037A/ja active Pending
- 2016-08-24 EP EP16840069.5A patent/EP3340967B1/en active Active
- 2016-08-24 WO PCT/US2016/048492 patent/WO2017035278A1/en active Application Filing
-
2018
- 2018-02-06 IL IL257376A patent/IL257376B/en unknown
- 2018-02-13 ZA ZA2018/00977A patent/ZA201800977B/en unknown
- 2018-02-23 US US15/904,224 patent/US10731157B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3340967B1 (en) | 2024-05-22 |
IL257376B (en) | 2022-04-01 |
CA2995995A1 (en) | 2017-03-02 |
US20190055555A1 (en) | 2019-02-21 |
IL257376A (en) | 2018-04-30 |
EP3340967A4 (en) | 2019-08-14 |
US10731157B2 (en) | 2020-08-04 |
BR112018003784A2 (pt) | 2018-09-25 |
AU2016312530A1 (en) | 2018-03-01 |
MX2018002090A (es) | 2018-09-12 |
ZA201800977B (en) | 2020-05-27 |
EP3340967A1 (en) | 2018-07-04 |
WO2017035278A1 (en) | 2017-03-02 |
CN108366966A (zh) | 2018-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10731157B2 (en) | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof | |
US9957505B2 (en) | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof | |
JP6718872B2 (ja) | 標的化rna編集 | |
CA2546669C (en) | Sequence-specific inhibition of small rna function | |
US9457046B2 (en) | Compounds for the treatment of ischemic injury | |
US20110159586A1 (en) | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides | |
JP2008526213A (ja) | 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法 | |
JP2008278784A (ja) | 1本鎖環状rnaおよびその製造方法 | |
BRPI0619755A2 (pt) | micrornas que regulam a proliferação e diferenciação de células musculares | |
WO2005095613A1 (ja) | Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用 | |
US20100292299A1 (en) | Nucleotide Motifs Providing Localization Elements and Methods of Use | |
JP5744375B2 (ja) | イントロンrna技術を用いる組み換え型核酸組成物及び同組み換え型核酸組成物を含む化粧品 | |
Maksimenko et al. | Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma | |
Okamoto et al. | The therapeutic potential of RNA interference: novel approaches for cancer treatment | |
TW201119681A (en) | Compositions and methods for inhibiting expression of KIF10 genes | |
KR20220169178A (ko) | 타겟 유전자 발현을 조절할 수 있는 헤어핀 구조의 핵산 분자 및 이의 용도 | |
L Hefferon | Innovations in siRNA research: A technology comes of age | |
Jian et al. | RNA therapy: Are we using the right molecules? | |
KR100929700B1 (ko) | 일부 단일가닥의 다중 간섭 유도 rna | |
ES2764699T3 (es) | Molécula de miARN definida por su fuente y sus usos diagnósticos y terapéuticos en enfermedades o afecciones asociadas a la TEM | |
Tuma | Using the Cell's Own Tools to Turn Down Gene Expression | |
Heinonen | Molecular dissection of Bruton s tyrosine kinase signaling in hematopoietic cells using RNAi | |
Hernandes | Antisense Elements (genetics) Research Focus | |
CN108310381A (zh) | 通过miR-6511b-3p进行抗癌的方法和药物及其应用 | |
EP2491950A1 (fr) | Préparations homéopathiques à base d'ARNi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180608 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200923 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210427 |